 Ditiocarb sodium diethyldithiocarbamate therapy patients symptomatic HIV infection AIDS randomized double-blind placebo-controlled multicenter study symptomatic patients human immunodeficiency virus HIV infection sodium weeks placebo Patients Disease Control CDC group cell number duration disease entry new immunodeficiency syndrome AIDS opportunistic infections treated patients controls Reduction new opportunistic infections ditiocarb group significant patients relative risk RR patients AIDS CDC groups IV-D RR size effect ditiocarb data exclusion patient Pneumocystis carinii pneumonia CDC-defined RR new opportunistic infections events active entry definitive diagnosis study RR administration ditiocarb major adverse clinical biological reactions study ditiocarb safe incidence opportunistic infections patients symptomatic HIV infection